Challenges and opportunities in designing clinical trials for neuromyelitis optica

Guthy-Jackson Charitable Foundation International Clinical Consortium

Research output: Contribution to journalReview articlepeer-review

33 Scopus citations


Current management of neuromyelitis optica (NMO) is noncurative and only partially effective. Immunosuppressive or immunomodulatory agents are the mainstays of maintenance treatment. Safer, better-tolerated, and proven effective treatments are needed. The perceived rarity of NMO has impeded clinical trials for this disease. However, a diagnostic biomarker and recognition of a wider spectrum of NMO presentations has expanded the patient population from which study candidates might be recruited. Emerging insights into the pathogenesis of NMO have provided rationale for exploring new therapeutic targets. Academic, pharmaceutical, and regulatory communities are increasingly interested in meeting the unmet needs of patients with NMO. Clinical trials powered to yield unambiguous outcomes and designed to facilitate rapid evaluation of an expanding pipeline of experimental agents are needed. NMO-related disability occurs incrementally as a result of attacks; thus, limiting attack frequency and severity are critical treatment goals. Yet, the severity of NMO and perception that currently available agents are effective pose challenges to study design. We propose strategies for NMO clinical trials to evaluate agents targeting recovery from acute attacks and prevention of relapses, the 2 primary goals of NMO treatment. Aligning the interests of all stakeholders is an essential step to this end.

Original languageEnglish (US)
Pages (from-to)1805-1815
Number of pages11
Issue number17
StatePublished - Apr 28 2015

ASJC Scopus subject areas

  • Clinical Neurology


Dive into the research topics of 'Challenges and opportunities in designing clinical trials for neuromyelitis optica'. Together they form a unique fingerprint.

Cite this